Edward O. Lanphier II
About Edward O. Lanphier II
Edward O. Lanphier II is the Executive Chair with over 30 years of experience in the biotech industry, known for his work in genome editing at Sangamo Therapeutics.
Edward O. Lanphier II Executive Chair
Edward O. Lanphier II currently serves as an Executive Chair. With a career spanning over three decades, he has a wealth of experience in the biotech industry. He has expertise in various facets of therapeutic development, from initial research to clinical applications, giving him a comprehensive understanding of the biotech field.
Edward O. Lanphier II Former CEO of Sangamo Therapeutics
Edward O. Lanphier II formerly served as the CEO of Sangamo Therapeutics. During his tenure, he was instrumental in pioneering the field of genome editing. Under his leadership, Sangamo Therapeutics became a notable entity in the biotech industry, focusing on innovative approaches to gene therapy and genome editing.
Edward O. Lanphier II Experience at Synergen and Eli Lily
Before his role at Sangamo Therapeutics, Edward O. Lanphier II held significant positions in other prominent biotech firms, including Synergen and Eli Lily. These roles allowed him to gain extensive experience in the industry, contributing to his robust expertise in developing therapeutics.
Edward O. Lanphier II Chairman of the Board at Alliance for Regenerative Medicine
Edward O. Lanphier II also served as the Chairman of the Board at the Alliance for Regenerative Medicine. In this role, he played a key part in advancing the mission of the organization, which focuses on promoting regenerative medicine and garnering support for the development of innovative medical treatments.
Edward O. Lanphier II 30 Years in the Biotech Industry
With over 30 years in the biotech industry, Edward O. Lanphier II has established a remarkable career dedicated to advancing therapeutic developments. His extensive experience ranges from hands-on bench research to clinical implementation, providing him with a comprehensive perspective on the complete lifecycle of therapeutic innovations.